Xconomy’s Digital Events →
September 24, 2020 · National
November 17, 2020 · New York
Matthew Scholz is the CEO of Immusoft, a (currently) Seattle based biotech startup that is commercializing technology to program the human immune system.
If Seattle is to occupy a future place of dominance in the biotech world, it must foster more of an “incubator” culture. There is a “valley of death” between the well-funded... Read more »
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
© 2007-2020, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.